GLMD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases...

Stats
Today's Volume	22 393.00
Average Volume	210 193
Market Cap	2.33M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $0 ) 2024-05-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0.00800 (2.07%)

Volume Correlation

Long: -0.12 (neutral)

Short: -0.22 (neutral)

Signal:(52.983) Neutral

Galmed Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations
RMRM	-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Galmed Pharmaceuticals Correlation - Currency/Commodity

-0.58
( weak negative )

-0.61
( weak negative )

0.00
( neutral )

0.42
( neutral )

Galmed Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-31 000.00 (0.00 %)
EPS:	$-2.50

FY	2023
Revenue:	$0
Gross Profit:	$-31 000.00 (0.00 %)
EPS:	$-2.50

FY	2022
Revenue:	$0
Gross Profit:	$-35 000.00 (0.00 %)
EPS:	$-11.08

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.320

Financial Reports:

No articles found.

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.